Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Wellcome Trust ISSF call deadline 30 January

Research

The first Wellcome Trust Institutional Strategic Support Fund (ISSF) call for 2014-15 is now open, and welcomes proposals on a broad range of themes from any department in the University. Research projects must fall within the remit of the Wellcome Trust, as well as the strategic remit of biomedical research at Oxford.

The deadline is Friday 30 January 2015. 

Read more on the ISSF website

Similar stories

Multi-partner 'OpenMind' consortium to develop technology for new generation of neurostimulation devices

General Research

Investigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.

Why we must expand newborn screening

General Research

Professor Laurent Servais of the Department of Paeditrics writes for the Oxford Science Blog on why it is important that we become much more efficient in the diagnosis of treatable conditions and in the treatment of these diseases.

Severe COVID in young people can mostly be explained by obesity – new study

General Research

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

Coronavirus COVID-19 General Research

New method for cost-effective genome-wide DNA methylation analysis

General Research

Ludwig Cancer Research team build on its TAPS method to develop an alternative to costly whole-genome sequencing for the detection of DNA methylation.

Azithromycin not effective against COVID-19, trial confirms

Clinical Trials General Research

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.